Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effexor Will Rebound After “Cloud” Over Antidepressant Class Lifts, Wyeth Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Antidepressant growth has stalled amid publicity surrounding pediatric safety data, Wyeth acknowledges. Company still expects Effexor to top $3 bil. this year, helped by strong international sales.

You may also be interested in...



Off-Label Promotion, Class Labeling Debated During Antidepressant Hearing

The congressional investigation into antidepressants could renew interest in how off-label promotion is regulated in the U.S

Virtual Advisory Committees: US FDA Clears A Big Test With OxyContin Meeting

Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.

Trump’s Drug Pricing Plan: The Headlines Are The Goal – But Also A Threat

The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel